Alterity Therapeutics (ATHE) Cash from Investing Activities (2016 - 2019)

Alterity Therapeutics' Cash from Investing Activities history runs 4 years deep, the most recent figure standing at -$5123.2 for Q4 2019.

• In Q4 2019, Cash from Investing Activities fell 118.19% year-over-year to -$5123.2; the TTM figure through Dec 2019 stood at -$26661.1 (up 41.26% YoY), while the FY2025 annual figure was -$4.8 million, down 127275.44% from the prior year.
• Cash from Investing Activities for Q4 2019 stood at -$5123.2, down from -$2348.0 in the prior quarter.
• The five-year high for Cash from Investing Activities was -$2348.0 in Q4 2018, with the low at -$16622.8 in Q4 2016.
• The 4-year median for Cash from Investing Activities is -$3845.1 (2017), against an average of -$6665.3.
• The sharpest annual moves came in 2017 and 2019: Cash from Investing Activities jumped 84.56% in 2017, then plunged 118.19% in 2019.
• Alterity Therapeutics' Cash from Investing Activities stood at -$16622.8 in 2016, then surged by 84.56% to -$2567.1 in 2017, then rose by 8.53% to -$2348.0 in 2018, then plunged by 118.19% to -$5123.2 in 2019.
• Business Quant data shows ATHE's Cash from Investing Activities at -$5123.2 in Q4 2019, -$2348.0 in Q4 2018, and -$2567.1 in Q4 2017.